Several drugs, including thiazolidinediones (peroxisome proliferator-activated receptor gamma (PPARγ) agonists that are insulin sensitizers) are being investigated as therapies to reduce hepatic steatosis, inflammation, and fibrosis [5,6]. The gene discussed is INS; the disease is Hepatic steatosis.